Daniel R. Chevallard
2018
In 2018, Daniel R. Chevallard earned a total compensation of $983.6K as Chief Financial Officer at Regulus Therapeutics, a 69% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $124,800 |
|---|---|
| Option Awards | $535,241 |
| Salary | $312,000 |
| Other | $11,526 |
| Total | $983,567 |
Chevallard received $535.2K in option awards, accounting for 54% of the total pay in 2018.
Chevallard also received $124.8K in non-equity incentive plan, $312K in salary and $11.5K in other compensation.
Rankings
In 2018, Daniel R. Chevallard's compensation ranked 9,278th out of 14,244 executives tracked by ExecPay. In other words, Chevallard earned more than 34.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,278 out of 14,244 | 35th |
Division Manufacturing | 3,710 out of 5,765 | 36th |
Major group Chemicals And Allied Products | 1,396 out of 2,128 | 34th |
Industry group Drugs | 1,173 out of 1,817 | 35th |
Industry Pharmaceutical Preparations | 910 out of 1,391 | 35th |
Source: SEC filing on July 1, 2019.
Chevallard's colleagues
We found two more compensation records of executives who worked with Daniel R. Chevallard at Regulus Therapeutics in 2018.